- Home
- VIP vs MCRB Comparison
VIP vs MCRB Comparison
Compare VIP & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIP | MCRB |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 41.2M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VIP | MCRB |
|---|---|---|
| Price | $1.63 | $3.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 127.0K | 46.4K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,388,000.00 | $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.55 | $3.52 |
| 52 Week High | $2.74 | $29.98 |
Technical Indicators
Market Signals| Indicator | VIP | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 26.87 |
| Support Level | $1.55 | N/A |
| Resistance Level | $1.98 | $5.80 |
| Average True Range (ATR) | 0.11 | 0.35 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 0.03 | 1.78 |
Price Performance
Historical ComparisonAbout VIP Vulcan Infrastructure and Power Inc. Class A Common Stock
Vulcan Infrastructure and Power Inc is a power and infrastructure platform focused on acquiring, developing and operating energized sites that support artificial intelligence and high-performance computing data centers, as well as local electricity grids.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.